Status: Recruiting
A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease
Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shandong First Medical UniversityUpdated: Apr 6, 2026Locations: 1
Eligibility criteria
1. Confirmed diagnosis of autoimmune bullous disease; [+2]
1. History of clinically significant diseases that, in the investigator's judgme... [+3]